GNLX Penghasilan resik perusahaan Genelux Corp

The price history on the Genelux Corporation (GNLX) chart on the GURU.Markets platform reflects the dynamics of a company developing innovative tumor treatment methods. The current indicator is -0.04. Financial stability is constrained by a lack of regular profits due to the R&D stage, leaving the business dependent on investments. Meanwhile, Thomas Zindrick's management is successfully conducting phase II trials, maintaining market confidence through its scientific foundation.

GNLX genelux.com: Penghasilan resik ing interval 28.04.2023 - 01.11.2026

Rincian analitis lan laporan data perusahaan genelux.com (GNLX)

- rega saham lan konsensus proyeksi valuasi:

Bagan rega Genelux|GNLX - Bagan rega target

- data kapitalisasi pasar:

Nilai pasar Genelux Corporation|GNLX - Nilai Perusahaan

- data ekuitas miturut neraca:

Nilai Buku Siji Saham Genelux|GNLX - Aset Bersih Perusahaan|Koefisien Nilai Pasar marang Nilai Buku genelux.com|GNLX - Gunggung Aset Perusahaan

- indikator beban utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi Genelux Corporation|GNLX - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang ekuitas Genelux|GNLX - Utang perusahaan|Rasio utang marang kapitalisasi buku Genelux Corporation|GNLX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Genelux|Rasio likuiditas perantara genelux.com

- data bathi bisnis lan rasio investasi:

GNLX - Bathi resik

Analisis dhasar perusahaan:Genelux Corp, GNLX

Assessing the financial stability of Genelux Corporation (GNLX) requires an analysis of its ability to generate real income. This indicator measures the bottom-line financial result after deducting all operating expenses and taxes. The trend in the company's reported net profit reflects the efficiency of the business's adaptation to current US interest rates and monetary conditions. For this developer of oncolytic viruses, this metric demonstrates a transition from the investment phase to the commercialization of therapy. Steady growth in this metric confirms the viability of the new cancer immunotherapy model.

Pesaing langsung

GERN (Geron Bio) - Bathi resik perusahaan|Bathi resik perusahaan Nanobiotix S.A.|Penghasilan resik perusahaan bicycletherapeutics.com BCYC|Bathi resik CTMX|perspectivetherapeutics.com (CATX) - Bathi resik taunan|Molecular Partners - Penghasilan resik|Oncolytics Biotech, Inc. (ONCY) - Penghasilan resik perusahaan|LSTA: Penghasilan resik|Bathi pungkasan MBRX (Moleculin Biotech, Inc.)|galeratx.com (GRTX) - Bathi resik perusahaan|Bathi sawise pajeg MTEM (Molecular Templates Inc)